Skip to main content
SpringerLink
Log in
Book cover

RNA Vaccines pp 89–107Cite as

RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1499))

Abstract

Developing effective mRNA vaccines poses certain challenges concerning mRNA stability and ability to induce sufficient immune stimulation and requires a specific panel of techniques for production and testing. Here, we describe the production of stabilized mRNA with enhanced immunogenicity, generated using conventional nucleotides only, by introducing changes to the mRNA sequence and by complexation with the nucleotide-binding peptide protamine (RNActive® technology). Methods described here include the synthesis, purification, and protamine complexation of mRNA vaccines as well as a comprehensive panel of in vitro and in vivo methods for evaluation of vaccine quality and immunogenicity.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Schlake T, Thess A, Fotin-Mleczek M, Kallen K-J (2012) Developing mRNA-vaccine technologies. RNA Biol 9:1319–1330. doi:10.4161/rna.22269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kallen K-J, Heidenreich R, Schnee M et al (2013) A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccin Immunother 9:2263–2276. doi:10.4161/hv.25181

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kallen K-J, Theß A (2014) A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2:10–31. doi:10.1177/2051013613508729

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kübler H, Scheel B, Gnad-Vogt U et al (2015) Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 3:26. doi:10.1186/s40425-015-0068-y

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sebastian M, Papachristofilou A, Weiss C et al (2014) Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14:748. doi:10.1186/1471-2407-14-748

    Article  PubMed  PubMed Central  Google Scholar 

  6. Petsch B, Schnee M, Vogel AB et al (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30:1210–1216. doi:10.1038/nbt.2436

    Article  CAS  PubMed  Google Scholar 

  7. Pardi N, Muramatsu H, Weissman D, Karikó K (2013) In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol 969:29–42. doi:10.1007/978-1-62703-260-5_2

    Article  CAS  PubMed  Google Scholar 

  8. Strong TV, Hampton TA, Louro I et al (1997) Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression. Gene Ther 4:624–627. doi:10.1038/sj.gt.3300423

    Article  CAS  PubMed  Google Scholar 

  9. Weissman D, Pardi N, Muramatsu H, Karikó K (2013) HPLC purification of in vitro transcribed long RNA. Methods Mol Biol Clifton NJ 969:43–54. doi:10.1007/978-1-62703-260-5_3

    Article  CAS  Google Scholar 

  10. Thess A, Grund S, Mui BL et al (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23:1456–1464. doi:10.1038/mt.2015.103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fotin-Mleczek M, Duchardt KM, Lorenz C et al (2011) Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34:1–15. doi:10.1097/CJI.0b013e3181f7dbe8

    Article  CAS  PubMed  Google Scholar 

  12. Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109:14604–14609. doi:10.1073/pnas.1209367109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kreiter S, Selmi A, Diken M et al (2010) Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031–9040. doi:10.1158/0008-5472.CAN-10-0699

    Article  CAS  PubMed  Google Scholar 

  14. Midoux P, Pichon C (2015) Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines 14:221–234. doi:10.1586/14760584.2015.986104

    Article  CAS  PubMed  Google Scholar 

  15. Warren L, Manos PD, Ahfeldt T et al (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618–630. doi:10.1016/j.stem.2010.08.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was partly funded by the German Federal Ministry of Education and Research (BMBF, grant number: 031A061A).

Author information

Authors and Affiliations

  1. CureVac AG, Paul-Ehrlich-Str. 15, 72076, Tübingen, Germany

    Susanne Rauch, Johannes Lutz, Aleksandra Kowalczyk, Thomas Schlake & Regina Heidenreich

Authors
  1. Susanne Rauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aleksandra Kowalczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Schlake
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Regina Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Regina Heidenreich .

Editor information

Editors and Affiliations

  1. Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany

    Thomas Kramps

  2. Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

    Knut Elbers

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this protocol

Cite this protocol

Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T., Heidenreich, R. (2017). RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines. In: Kramps, T., Elbers, K. (eds) RNA Vaccines. Methods in Molecular Biology, vol 1499. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6481-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6481-9_5

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6479-6

  • Online ISBN: 978-1-4939-6481-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation